Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Rhea-AI Summary

Immutep (NASDAQ: IMMP) announced that data from its EFTISARC-NEO Phase II trial has been accepted for oral presentation at the CTOS 2025 Annual Meeting. The groundbreaking study evaluates eftilagimod alpha (efti) in combination with radiotherapy and KEYTRUDA® for soft tissue sarcoma (STS) patients in a neoadjuvant setting.

The presentation will be delivered by Dr. Pawel Sobczuk on November 13, 2025, focusing on the primary endpoint and translational correlates from the trial. This research addresses a significant unmet medical need, as STS affects approximately 13,520 new patients in the US annually, with an estimated 5,420 deaths in 2025.

The study is being conducted at the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, with primary funding from the Polish government.

News Market Reaction – IMMP

+4.24% 1.7x vol

5 alerts

+4.24% News Effect

-10.6% Trough in 31 hr 37 min

+$10M Valuation Impact

$241M Market Cap

1.7x Rel. Volume

On the day this news was published, IMMP gained 4.24%, reflecting a moderate positive market reaction. Argus tracked a trough of -10.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $241M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

• Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting
  
  

 SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract for the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting taking place 12-15 November 2025, in Boca Raton, Florida.

EFTISARC-NEO is the first study to evaluate eftilagimod alpha (efti) in a neoadjuvant setting (prior to surgery) administered in combination with radiotherapy plus KEYTRUDA^® (pembrolizumab) for patients with soft tissue sarcoma (STS).

Presentation Details
Title:	Primary endpoint and translational correlates from EFTISARC-NEO: phase II trial of neoadjuvant eftilagimod alpha (efti), pembrolizumab, and radiotherapy in patients with resectable soft tissue sarcoma
Session:	Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers
Presenter:	Pawel Sobczuk, M.D., Ph.D., Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
Date:	Thursday, 13 November 2025, 1:30 PM – 3:00 PM ET
Format:	Oral Presentation

STS is an orphan disease with high unmet medical need and a poor prognosis for patients. The incidence of STS varies in different regions globally. In the United States, the number of new STS cases in 2025 is estimated to be ~13,520 with ~5,420 deaths, according to the American Cancer Society.¹

EFTISARC-NEO is is being conducted by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland. The study is primarily funded with an approved grant from the Polish government awarded by the Polish Medical Research Agency program. For more information on the trial visit clinicaltrials.gov (NCT06128863).

The presentation slides will be available on the Posters & Publications section of Immutep’s website after the presentation at CTOS 2025.

About Immutep

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

1. American Cancer Society statistics: https://www.cancer.org/cancer/types/soft-tissue-sarcoma/about/key-statistics.html

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Investors/Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com

FAQ

What is the EFTISARC-NEO Phase II trial by Immutep (NASDAQ: IMMP) studying?

The EFTISARC-NEO trial is studying eftilagimod alpha (efti) in combination with radiotherapy and KEYTRUDA® in a neoadjuvant setting for soft tissue sarcoma patients before surgery.

When and where will Immutep present the EFTISARC-NEO trial data at CTOS 2025?

The data will be presented on Thursday, November 13, 2025, from 1:30 PM to 3:00 PM ET at the CTOS Annual Meeting in Boca Raton, Florida.

What is the current impact of soft tissue sarcoma (STS) in the United States?

According to the American Cancer Society, there will be approximately 13,520 new STS cases and 5,420 deaths in the United States in 2025.

Who is funding the EFTISARC-NEO trial for Immutep?

The study is primarily funded through a grant from the Polish government, awarded by the Polish Medical Research Agency program.

Where can investors find the EFTISARC-NEO presentation materials after CTOS 2025?

The presentation slides will be available in the Posters & Publications section of Immutep's website after the CTOS 2025 presentation.